metamorworks
Cantor Fitzgerald recently revealed its optimism for the medtech sector in 2024 by naming AVITA Medical (NASDAQ:RCEL) as its top medtech idea, while maintaining its bullish outlook on Axogen (NASDAQ:AXGN), Cerus (NASDAQ:CERS), Elutia (ELUT), Exagen (XGN), NANO-X (NNOX), NeuroPace (NPCE), Nyxoah (NYXH), SI-BONE (SIBN), and Pacific Biosciences (NASDAQ:PACB).
RCEL – Rising Star of Medtech
AVITA Medical was described as a standout choice due to its impressive growth rate of approximately 64% year-over-year and robust gross margins of about 85%. Cantor analysts even went as far as to suggest that it should trade at a premium to its peers, lauding the company’s superior growth profile and best-in-class gross margins.
PACB – A Sound Entry Point
On the other hand, Cantor expressed confidence in Pacific Biosciences, referring to the recent selloff in its shares as a “sound entry point” for investors who can look past short-term hurdles. The firm highlighted PacBio’s strong position in the long-read and short-read sequencing markets, emphasizing the stock’s appeal to long-term investors.
AXGN – Undervalued Takeout Candidate
Cantor also held a positive view on AxoGen, identifying it as a prime acquisition target and underscoring its revenue momentum, supported by robust clinical data, product launches, and an expanded focus on innovative procedures.
CERS, ELUT, XGN, NPCE, NYXH, SIBN – Path to Profitability
The investment bank encouraged investors to revisit the Cerus story, recognizing an improved operating environment, a return to revenue growth, and a clear trajectory towards sustained profitability. Additionally, Cantor highlighted Elutia’s potential pending FDA approval for CanGarooRM, which could lead to significant revenue. The firm also forecasted positive price appreciation for Exagen this year and raised its price target for NeuroPace, touting its ability to surpass revenue expectations. For Nyxoah and SI-BONE, Cantor emphasized significant upcoming catalysts and anticipated strong revenue growth, respectively.
Summing Up
It’s evident that Cantor’s choices reflect a blend of optimism, caution, and calculated risk-taking. Their selections are steeped in a deep understanding of each company’s intricacies, coupled with a keen eye on the evolving landscape of the medtech industry. And while the dashboard may indicate some near-term turbulence, for investors with a steady hand and a discerning eye, these may very well be the stars to hitch their wagons to.
More on Pacific Biosciences of California, AVITA Medical, etc.
